Phio Pharmaceuticals Appoints New VP of Finance and Administration

Form 3 Initial Statement of Beneficial Ownership filed by Lisa Cabott Carson for Phio Pharmaceuticals (NASDAQ: PHIO) on June 28, 2025, reporting her beneficial ownership position as of June 6, 2025.

Rhea-AI Filing Summary

Form 3 Initial Statement of Beneficial Ownership filed by Lisa Cabott Carson for Phio Pharmaceuticals (NASDAQ: PHIO) on June 28, 2025, reporting her beneficial ownership position as of June 6, 2025.

Key details:

• Carson has been appointed as VP, Finance and Administration at Phio Pharmaceuticals
• Currently holds no beneficial ownership of any securities, either direct or indirect
• Filing includes no derivative securities ownership (options, warrants, etc.)
• Individual filing submitted with Power of Attorney documentation (Exhibit 24)

This Form 3 establishes the baseline ownership position for the new officer's future transaction reporting requirements under SEC Section 16(a).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the new VP of Finance and Administration at PHIO Pharmaceuticals (PHIO)?

Lisa Cabott Carson was appointed as VP of Finance and Administration at PHIO Pharmaceuticals, as disclosed in a Form 3 filing dated June 28, 2025.

When did Lisa Carson join PHIO Pharmaceuticals (PHIO) as an officer?

According to the Form 3 filing, the date of event requiring statement was June 6, 2025, which indicates when Lisa Carson became an officer (VP of Finance and Administration) at PHIO Pharmaceuticals.

Does Lisa Carson own any shares of PHIO Pharmaceuticals stock?

No, according to the Form 3 filing, Lisa Carson does not beneficially own any securities of PHIO Pharmaceuticals. This is explicitly stated in the 'Remarks' section: 'No securities are beneficially owned.'

What position does Lisa Carson hold at PHIO Pharmaceuticals (PHIO)?

Lisa Carson holds the position of Vice President of Finance and Administration at PHIO Pharmaceuticals, as disclosed in the Form 3 filing under Section 4 'Relationship of Reporting Person(s) to Issuer.'

Where is PHIO's new VP of Finance and Administration based?

According to the Form 3 filing, Lisa Carson's business address is at PHIO Pharmaceuticals Corp.'s headquarters at 11 Apex Dr., Suite 300A, PMB 2006, Marlborough, MA 01752.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2025 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Carson Lisa Cabott

(Last) (First) (Middle)

C/O PHIO PHARMACEUTICALS CORP.

11 APEX DR., SUITE 300A, PMB 2006

(Street)

MARLBOROUGH MA 01752

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
06/06/2025

3. Issuer Name and Ticker or Trading Symbol
Phio Pharmaceuticals Corp. [ PHIO ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Finance and Administration

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Lisa C. Carson	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.